Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued on Wednesday. The brokerage set a “hold” rating on the stock.

Several other equities research analysts have also recently weighed in on EKSO. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a report on Tuesday, January 14th. Lake Street Capital cut their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of Ekso Bionics stock opened at $0.63 on Wednesday. The stock has a 50 day moving average price of $0.68 and a 200-day moving average price of $0.94. Ekso Bionics has a one year low of $0.50 and a one year high of $2.50. The stock has a market cap of $13.92 million, a price-to-earnings ratio of -0.97 and a beta of 1.47. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The firm had revenue of $4.13 million for the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Equities analysts expect that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.